• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2012年至2020年北领地偏远地区2型糖尿病原住民中钠-葡萄糖协同转运蛋白2抑制剂的使用情况

Use of sodium-glucose cotransporter-2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020.

作者信息

Hare Matthew J L, Chen Winnie, Berhane Thomas, Corpus Sumaria M, Maple-Brown Louise J

机构信息

Endocrinology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia.

Wellbeing and Chronic Preventable Diseases Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.

出版信息

Intern Med J. 2025 Mar;55(3):518-522. doi: 10.1111/imj.16653. Epub 2025 Feb 24.

DOI:10.1111/imj.16653
PMID:39989248
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11900843/
Abstract

Aboriginal people in remote Northern Territory communities experience the highest burden of type 2 diabetes (T2D) globally. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiac and renal outcomes in selected populations. However, safety in this context is unknown. We investigated SGLT2i use and outcomes in remote Aboriginal people with T2D between 2012 and 2020.

摘要

澳大利亚北领地偏远社区的原住民承受着全球最高的2型糖尿病（T2D）负担。钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）可改善特定人群的心脏和肾脏预后。然而，在这种情况下其安全性尚不清楚。我们调查了2012年至2020年间偏远地区患有T2D的原住民使用SGLT2i的情况及其预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7c0/11900843/4a6f59168e2c/IMJ-55-518-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7c0/11900843/8f0c23f99647/IMJ-55-518-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7c0/11900843/4a6f59168e2c/IMJ-55-518-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7c0/11900843/8f0c23f99647/IMJ-55-518-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7c0/11900843/4a6f59168e2c/IMJ-55-518-g001.jpg

相似文献

1
Use of sodium-glucose cotransporter-2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020.2012年至2020年北领地偏远地区2型糖尿病原住民中钠-葡萄糖协同转运蛋白2抑制剂的使用情况
Intern Med J. 2025 Mar;55(3):518-522. doi: 10.1111/imj.16653. Epub 2025 Feb 24.
2
Epidemiology, etiology, and motivation of alcohol misuse among Australian Aboriginal and Torres Strait Islanders of the Northern Territory: a descriptive review.北领地澳大利亚原住民和托雷斯海峡岛民酒精滥用的流行病学、病因及动机：描述性综述
J Ethn Subst Abuse. 2015;14(1):1-11. doi: 10.1080/15332640.2014.958642. Epub 2015 Jan 28.
3
Defining the gap: a systematic review of the difference in rates of diabetes-related foot complications in Aboriginal and Torres Strait Islander Australians and non-Indigenous Australians.界定差距：对澳大利亚原住民和托雷斯海峡岛民与非原住民澳大利亚人糖尿病相关足部并发症发生率差异的系统评价。
J Foot Ankle Res. 2017 Nov 7;10:48. doi: 10.1186/s13047-017-0230-5. eCollection 2017.
4
Reducing Methamphetamine Use in Aboriginal and Torres Strait Islander Communities With the "We Can Do This" Web App: Qualitative Evaluation of Acceptability and Feasibility.使用“We Can Do This”网络应用程序减少原住民和托雷斯海峡岛民社区的甲基苯丙胺使用情况：可接受性和可行性的定性评估
JMIR Form Res. 2025 Jul 15;9:e58369. doi: 10.2196/58369.
5
Sodium-glucose cotransporter 2 inhibitors and inverse risk of new-onset atopic dermatitis in a cohort with diabetes: a nationwide active-comparator study.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病队列中新发特应性皮炎的反向风险：一项全国性活性对照研究
Br J Dermatol. 2025 Jun 20;193(1):74-84. doi: 10.1093/bjd/ljaf086.
6
Retrospective cross-sectional study on bronchiectasis in adult Aboriginal Australians: disease characteristics and comparison with ethnically diverse global bronchiectasis registry cohorts.澳大利亚成年原住民支气管扩张症的回顾性横断面研究：疾病特征及与全球不同种族支气管扩张症登记队列的比较
BMJ Open Respir Res. 2025 Jan 21;12(1):e002139. doi: 10.1136/bmjresp-2023-002139.
7
Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes.在患有 2 型糖尿病的患者中，临床实践中 SGLT2 抑制剂的心血管风险。
JAMA Netw Open. 2024 Oct 1;7(10):e2441765. doi: 10.1001/jamanetworkopen.2024.41765.
8
Aboriginal and Torres Strait Islander Complex Trauma and Strengths Questionnaire: psychometric evaluation.原住民及托雷斯海峡岛民复杂创伤与优势问卷：心理测量学评估
Aust J Psychol. 2024 May 23;76(1):2335917. doi: 10.1080/00049530.2024.2335917. eCollection 2024.
9
Stakeholder perspectives on HPV vaccination uptake among Aboriginal and Torres Strait Islander adolescents via the school immunisation programmes in Queensland: a qualitative study.通过昆士兰学校免疫计划对原住民和托雷斯海峡岛民青少年人乳头瘤病毒疫苗接种情况的利益相关者观点：一项定性研究
BMJ Open. 2025 Jun 4;15(6):e097518. doi: 10.1136/bmjopen-2024-097518.
10
Hepatitis B genotypes in Aboriginal and Torres Strait Islander Australians: correlation with clinical course and implications for management.澳大利亚原住民和托雷斯海峡岛民中的乙型肝炎基因型：与临床病程的相关性及管理意义。
Intern Med J. 2024 Apr;54(4):647-656. doi: 10.1111/imj.16181. Epub 2023 Aug 7.

本文引用的文献

1
Tolerability and efficacy of sodium-glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study.
Intern Med J. 2023 Oct;53(10):1916-1918. doi: 10.1111/imj.16245. Epub 2023 Oct 4.
2
Pharmaceutical management of type 2 diabetes among Indigenous Australians living in urban or rural locations: a comparative study using a national general practice database.城乡居住的澳大利亚原住民 2 型糖尿病的药物治疗管理：利用国家一般实践数据库进行的比较研究。
Aust J Rural Health. 2023 Oct;31(5):979-990. doi: 10.1111/ajr.13032. Epub 2023 Aug 25.
3
Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).在心血管获益证据不断增加的时代，澳大利亚钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）和胰高血糖素样肽-1 受体激动剂（GLP-1RA）的使用趋势（2014-2022 年）。
Eur J Clin Pharmacol. 2023 Sep;79(9):1239-1248. doi: 10.1007/s00228-023-03539-8. Epub 2023 Jul 14.
4
Risk of kidney disease following a pregnancy complicated by diabetes: a longitudinal, population-based data-linkage study among Aboriginal women in the Northern Territory, Australia.澳大利亚北领地原住民女性中糖尿病合并妊娠后发生肾脏疾病的风险：一项基于人群的纵向数据链接研究。
Diabetologia. 2023 May;66(5):837-846. doi: 10.1007/s00125-023-05868-w. Epub 2023 Jan 18.
5
Prevalence and incidence of diabetes among Aboriginal people in remote communities of the Northern Territory, Australia: a retrospective, longitudinal data-linkage study.澳大利亚北领地偏远社区原住民中的糖尿病患病率和发病率：一项回顾性、纵向数据链接研究。
BMJ Open. 2022 May 15;12(5):e059716. doi: 10.1136/bmjopen-2021-059716.
6
Pancreatitis and post-pancreatitis diabetes in Central Australia.
Intern Med J. 2023 Apr;53(4):568-576. doi: 10.1111/imj.15620. Epub 2022 Aug 23.
7
Current evidence and practical guidance for the use of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes.目前用于 2 型糖尿病的钠-葡萄糖共转运蛋白 2 抑制剂的证据和实用指南。
Aust J Gen Pract. 2021 Apr;50(4):225-230. doi: 10.31128/AJGP-05-20-5432.
8
Incidence of lower limb amputation in Central Australia.澳大利亚中部下肢截肢的发生率。
Aust Health Rev. 2021 Jun;45(3):361-367. doi: 10.1071/AH20182.
9
The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.澳大利亚 2 型糖尿病药物治疗与社会经济地位和地理位置的关联：一项全国性登记研究。
Diabetologia. 2021 Feb;64(2):349-360. doi: 10.1007/s00125-020-05304-3. Epub 2020 Oct 20.
10
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.SGLT2 抑制剂与 2 型糖尿病患者心血管和肾脏结局的关联：一项荟萃分析。
JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.